Table of contents

  • Brand Names
  • Chemistry
  • Pharmacologic Category
  • Mechanism of Action
  • Therapeutic Use
  • Pregnancy and Lactation Implications
  • Contraindications
  • Warnings and Precautions
  • Adverse Reactions
  • Caution and personalized dose adjustment in patients with the following genotypes
  • Other genes that may be involved
  • Drug Interactions
  • Nutrition/Nutraceutical Interactions
  • Dosage
  • Pharmacokinetics and Pharmacodynamics
  • Special Considerations

Brand Names


Austria: Enbrel; Belgium: Enbrel; Bulgaria: Enbrel; Cyprus: Enbrel; Czech Republic: Enbrel; Denmark: Enbrel; Estonia: Enbrel; Finland: Enbrel; France: Enbrel; Germany: Enbrel; Greece: Enbrel; Hungary: Enbrel; Ireland: Enbrel; Italy: Enbrel; Latvia: Enbrel; Lithuania: Enbrel; Luxembourg: Enbrel; Malta: Enbrel; Netherlands: Enbrel; Poland: Enbrel; Portugal: Enbrel; Romania: Enbrel; Slovakia: Enbrel; Slovenia: Enbrel; Spain: Enbrel; Sweden: Enbrel; UK: Enbrel.

North America

Canada: Enbrel; USA: Enbrel.

Latin America

Argentina: Enbrel; Brazil: Enbrel; Mexico: Enbrel.


Japan: Enbrel.

Drug combinations


Etanercept: C~2224~H~3472~N~618~O~701~S~36~ (monomer). Mw: 51238.01 (non-glycosylated protein, monomer). 1-235-Tumor necrosis factor receptor (human) fusion protein with 236-467-immunoglobulin G~1~ (human γ1-chain Fc fragment), dimer. CAS-185243-69-0 (1998).

Pharmacologic Category

Biologic Response Modifiers. Disease-modifying Antirheumatic Drugs. Tumor Necrosis Factor (TNF) Blocking Agent. (ATC-Code: L04AB01).

Mechanism of action

A biologic response modifier which blocks the biologic activity of TNF and a disease-modifying antirheumatic drug. Binds TNF and blocks its interaction with cell surface receptors.

Therapeutic use

Treatment of moderately- to severely-active rheumatoid arthritis. Moderately- to severely-active polyarticular juvenile idiopathic arthritis. Psoriatic arthritis. Active ankylosing spondylitis. Moderate-to-severe chronic plaque psoriasis.

Pregnancy and lactiation implications

No studies in pregnant women. Drug should be used during pregnancy only if clearly needed. Not recommended during lactation.

Unlabeled use


Hypersensitivity to etanercept or any component of the formulation. Patients with sepsis (mortality may be increased). Active infections (including chronic or local infection).

Warnings and precautions

Allergic reactions may occur (anaphylaxis not observed). Rare cases of autoimmune disorder, including lupus-like syndrome or autoimmune hepatitis, reported. Rare reactivation of hepatitis B occurred in chronic carriers of the virus. Serious and potentially fatal infections reported, including bacterial sepsis and tuberculosis. Use may affect defenses against malignancies. Tuberculosis (disseminated or extrapulmonary) reported (reactivation of latent infection and new infections). Use with caution in pre-existing or recent onset CNS demyelinating disorders (rare cases of new onset or exacerbation of CNS demyelinating disorders have occurred). Optic neuritis, transverse myelitis, multiple sclerosis, and new onset or exacerbation of seizures reported. Use with caution in heart failure or decreased left ventricular function (worsening and new-onset heart failure reported). Use with caution in history of significant hematologic abnormalities (associated with pancytopenia and aplastic anemia). Use not recommended in patients with Wegener’s granulomatosis receiving immunosuppressive therapy (higher incidence of noncutaneous solid malignancies). Should not be used in combination with anakinra unless no satisfactory alternatives exist (higher incidence of serious infections). Patients with a significant exposure to varicella virus should temporarily discontinue therapy. Some dosage forms may contain dry natural rubber (latex). Live vaccines should not be given concurrently.



Legal Notice
Privacy Policy
Cookie Policy


Phone: +34-981-780505
Location: Sta Marta de, C. P. Babío, S/N, 15165 Bergondo, A Coruña

Copyright © 2023 WAGEM

Add to cart